Article
Erlotinib in lung cancer - molecular and clinical predictors of outcome.
The New England journal of medicine - 14 Jul 2005
Tsao Ming-Sound, Sakurada Akira, Cutz Jean-Claude, Zhu Chang-Qi, Kamel-Reid Suzanne, Squire Jeremy, Lorimer Ian, Zhang Tong, Liu Ni, Daneshmand Manijeh, Marrano Paula, da Cunha Santos Gilda, Lagarde Alain, Richardson Frank, Seymour Lesley, Whitehead Marlo, Ding Keyue, Pater Joseph, Shepherd Frances A
Abstract excerpt
BACKGROUND: A clinical trial that compared erlotinib with a placebo for non-small-cell lung cancer demonstrated a survival benefit for erlotinib. We used tumor-biopsy samples from participants in this trial to investigate whether responsiveness to erlotinib and its impact on survival were associated with expression by the tumor of epidermal growth factor receptor (EGFR) and EGFR gene amplification and mutations....
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.